Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study

Tang,Yuyan; He,Haidong; Sun,Weiqian; Hu,Pin; Chen,Xia; Xu,Xudong

doi:10.3892/mmr.2018.9413

Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study

Authors:
- Yuyan Tang
- Haidong He
- Weiqian Sun
- Pin Hu
- Xia Chen
- Xudong Xu
View Affiliations

Affiliations: Department of Nephrology, Minhang Branch, Zhongshan Hospital, Fudan University, Shanghai 201199, P.R. China
Published online on: August 21, 2018 https://doi.org/10.3892/mmr.2018.9413
Pages: 4103-4112

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently, there is no clear evidence that advocates the widespread use of corticosteroids for the treatment of immunoglobulin A nephropathy (IgAN) with minimal proteinuria (<1 g/day). The recent Kidney Disease: Improving Global Outcomes Clinical Practice Guideline recommends supportive corticosteroid treatment. In the present study, 45 IgAN patients with high renal pathological scores and minimal proteinuria were enrolled. The patients were randomly divided into two groups. The treatment group received methylprednisolone tablets in addition to angiotensin‑converting‑enzyme inhibitor (ACE‑I) and/or angiotensin‑receptor blocker (ARB) treatment. The control group only received ACE‑I and/or ARB treatment. In the treatment group, a single dose of 1 mg/kg (maximum 60 mg/day) methylprednisolone tablets was given daily followed by gradually decreasing dosage. The follow‑up time of the patients was 3 years. In addition, the underlying mechanisms were investigated. The results indicated that there was a significant reduction in the amount of urinary proteins in the treatment group compared with the control group. At the end of the follow‑up, the endpoint event rate of moderate or severe proteinuria and decrease in estimated glomerular filtration rate (eGFR) in the treatment group was significantly lower than the control group. Furthermore, higher levels of serum cytokines, interleukin (IL)‑4, IL‑17, transforming growth factor‑β1 and IL‑21, were detected in patients with IgAN compared with a group of healthy controls. There was no significant difference in IFN‑γ expression between the IgAN and healthy control groups. Furthermore, the expression of Janus kinase (Jak)1, Jak3, signal transducer and activator of transcription (STAT)3 and STAT6 was significantly upregulated in patients with IgAN compared with healthy controls. However, the expression levels of STAT5 and chaperone protein, C1GALT1 specific chaperone 1, in IgAN patients were significantly reduced compared with healthy controls. In addition, there was no significant difference in the expression of Jak2, tyrosine kinase 2, STAT1 and STAT4 between the two groups. In conclusion, for IgAN patients with minimal proteinuria and high renal pathological score corticosteroid therapy is likely to be effective. The dysregulation of serum cytokine levels in these patients with IgAN may have a role in the pathogenesis and progression of disease, which is associated with the activation of the JAK/STAT signaling pathway.

View Figures

View References

1	Moresco RN, Speeckaert MM and Delanghe JR: Diagnosis and monitoring of IgA nephropathy: The role of biomarkers as an alternative to renal biopsy. Autoimmun Rev. 14:847–853. 2015. View Article : Google Scholar : PubMed/NCBI
2	Fabiano RC, Pinheiro SV and Simões E Silva AC: Immunoglobulin A nephropathy: A pathophysiology view. Inflamm Res. 65:757–770. 2016. View Article : Google Scholar : PubMed/NCBI
3	KDIGO clinical practice guidelines for glomerulonephritis, . 2012.Chapter 10: Immunoglobulin A nephropathy. Kidney Int Suppl. 2:S209–S217. View Article : Google Scholar
4	Glassock RJ: Glomerular disease: Targeted steroid therapy for IgA nephropathy. Nat Rev Nephron. 13:390–392. 2017. View Article : Google Scholar
5	Suzuki Y, Suzuki H, Makita Y, Takahata A, Takahashi K, Muto M, Sasaki Y, Kelimu A, Matsuzaki K, Yanagawa H, et al: Diagnosis and activity assessment of immunoglobulin A nephropathy: Current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers. Int J Nephrol Renovasc Dis. 7:409–414. 2014. View Article : Google Scholar : PubMed/NCBI
6	Yeo SC, Cheung CK and Barratt J: New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 33:763–777. 2018. View Article : Google Scholar : PubMed/NCBI
7	Robert T, Berthelot L, Cambier A, Rondeau E and Monteiro RC: Molecular insights into the pathogenesis of IgA nephropathy. Trends Mol Med. 21:762–775. 2015. View Article : Google Scholar : PubMed/NCBI
8	Hu S, Bao H, Xu X, Zhou X, Qin W, Zeng C and Liu Z: Increased miR-374b promotes cell proliferation and the production of aberrant glycosylated IgA1 in B cells of IgA nephropathy. FEBS Lett. 589:4019–4025. 2015. View Article : Google Scholar : PubMed/NCBI
9	Suzuki H, Allegri L, Suzuki Y, Hall S, Moldoveanu Z, Wyatt RJ, Novak J and Julian BA: Galactose-deficient IgA1 as a candidate urinary polypeptide marker of IgA nephropathy? Dis Markers 2016. 78064382016.
10	Knoppova B, Reily C, Maillard N, Rizk DV, Moldoveanu Z, Mestecky J, Raska M, Renfrow MB, Julian BA and Novak J: The origin and activities of IgA1-containing immune complexes in IgA nephropathy. Front Immunol. 7:1172016. View Article : Google Scholar : PubMed/NCBI
11	Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, et al: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 119:1668–1677. 2009.PubMed/NCBI
12	Tomino Y, Sakai H, Miura M, Endoh M and Nomoto Y: Detection of polymeric IgA in glomeruli from patients with IgA nephropathy. Clin Exp Immunol. 49:419–425. 1982.PubMed/NCBI
13	Lai KN, Ho RT, Leung JC, Lai FM and Li PK: Increased mRNA encoding for transforming factor-beta in CD4+ cells from patients with Ig Anephropathy. Kidney Int. 46:862–868. 1994. View Article : Google Scholar : PubMed/NCBI
14	Batra A, Smith AC, Feehally J and Barratt J: T-cell homing receptor expression in IgA nephropathy. Nephrol Nephrol Dial Transplant. 22:2540–2548. 2007. View Article : Google Scholar : PubMed/NCBI
15	Lai KN, Ho RT, Leung JC, Chui YL, Lim PL, Lui SF and Li PK: CD4-positive cells from patients with IgA nephropathy demonstrate increased mRNA of cytokines that induce the IgA switch and differentiation. J Pathol. 174:13–22. 1994. View Article : Google Scholar : PubMed/NCBI
16	Haas M: Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am J Kidney Dis. 6:829–842. 1997. View Article : Google Scholar
17	Katafuchi R, Kiyoshi Y, Oh Y, Uesugi N, Ikeda K, Yanase T and Fujimi S: Glomerular score as a prognosticator in IgA nephropathy: Its usefulness and limitation. Clin Nephrol. 49:1–8. 1998.PubMed/NCBI
18	Zhu Y, Ye X, Zhu B, Pei X, Wei L, Wu J and Zhao W: Comparisons between the 2012 New CKD-EPI (ChronicKidney Disease Epidemiology Collaboration) equations and other four approved equations. PLoS One. 9:e846882014. View Article : Google Scholar : PubMed/NCBI
19	Szeto CC and Li PK: MicroRNAs in IgA nephropathy. Nat Rev Nephrol. 10:249–256. 2014. View Article : Google Scholar : PubMed/NCBI
20	Rasche FM, Keller F, Rasche WG, Schiekofer S, Boldt A, Sack U and Fahnert J: Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy? Clin Exp Immunol. 186:115–133. 2016. View Article : Google Scholar : PubMed/NCBI
21	Park KS, Han SH, Kie JH, Nam KH, Lee MJ, Lim BJ, Kwon YE, Kim YL, An SY, Kim CH, et al: Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy. Hum Pathol. 45:236–243. 2014. View Article : Google Scholar : PubMed/NCBI
22	Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH and Katz AI: IgA nephropathy: Morphologic predictors of progressive renal disease. HUM Pathol. 13:314–22. 1982. View Article : Google Scholar : PubMed/NCBI
23	Haas M and Reich HN: Morphologic markers of progressive immunoglobulin A nephropathy. Adv Chronic Kidney Dis. 19:107–113. 2012. View Article : Google Scholar : PubMed/NCBI
24	Pozzi C: Treatment of IgA nephropathy. J Nephrol. 29:21–25. 2016. View Article : Google Scholar : PubMed/NCBI
25	Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D and Roberts ISD: Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. J Nephrol. 29:367–375. 2016. View Article : Google Scholar : PubMed/NCBI
26	O'Shaughnessy MM and Lafayette RA: Corticosteroids for IgA Nephropathy: TESTING for Benefit, Discovering Harm. JAMA. 318:429–431. 2017. View Article : Google Scholar : PubMed/NCBI
27	Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, et al: Risk factors for progression in children and young adults with IgA nephropathy: An analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol. 32:139–150. 2017. View Article : Google Scholar : PubMed/NCBI
28	Eitner F, Ackermann D, Hilgers RD and Floege J: Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: Rationale and study protocol. J Nephrol. 21:284–289. 2008.PubMed/NCBI
29	Nagy J, Sági B, Máté J, Vas T and Kovács T: Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN). Orv Hetil. 158:1946–1952. 2017.(In Hungarian). View Article : Google Scholar : PubMed/NCBI
30	Alvarado AS, Andeen NK, Brodsky S, Hinton A, Nadasdy T, Alpers CE, Blosser C, Najafian B and Rovin BH: Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant. 33:1168–1175. 2018. View Article : Google Scholar : PubMed/NCBI
31	Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, et al: GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet. 13:e10066092017. View Article : Google Scholar : PubMed/NCBI
32	Stuchlova Horynova M, Vrablikova A, Stewart TJ, Takahashi K, Czernekova L, Yamada K, Suzuki H, Julian BA, Renfrow MB, Novak J and Raska M: N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy. Nephrol Dial Transplant. 30:234–238. 2015. View Article : Google Scholar : PubMed/NCBI
33	Kiryluk K and Novak J: The genetics and immunobiology of IgA nephropathy. J Clin Invest. 124:2325–2332. 2014. View Article : Google Scholar : PubMed/NCBI
34	Ye M, Peng Y, Liu C, Yan W, Peng X, He L, Liu H and Liu F: Vibration induces BAFF overexpression and aberrant O-Glycosylation of IgA1 in cultured human tonsillar mononuclear cells in IgA nephropathy. Biomed Res Int. 2016:91259602016. View Article : Google Scholar : PubMed/NCBI
35	Ju T and Cummings RD: A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci USA. 99:pp. 16613–16618. 2002; View Article : Google Scholar : PubMed/NCBI
36	Meng H, Ohtake H, Ishida A, Ohta N, Kakehata S and Yamakawa M: IgA production and tonsillar focal infection in IgA nephropathy. J Clin Exp Hematop. 52:161–170. 2012. View Article : Google Scholar : PubMed/NCBI
37	Neurath MF, Finotto S and Glimcher LH: The role of Th1/Th2 polarization in mucosal immunity. Nat Med. 8:567–573. 2002. View Article : Google Scholar : PubMed/NCBI
38	He L, Peng Y, Liu H, Yin W, Chen X, Peng X, Shao J, Liu Y and Liu F: Activation of the interleukin-4/signal transducer and activator of transcription 6 signaling pathway and homeodomain-interacting protein kinase 2 production by tonsillar mononuclear cells in IgA nephropathy. Am J Nephrol. 38:321–332. 2013. View Article : Google Scholar : PubMed/NCBI
39	Liu L, Kou P, Zeng Q, Pei G, Li Y, Liang H, Xu G and Chen S: CD4+ T Lymphocytes, especially Th2 cells, contribute to the progress of renal fibrosis. Am J Nephrol. 36:386–396. 2012. View Article : Google Scholar : PubMed/NCBI
40	Yamada K, Kobayashi N, Ikeda T, Suzuki Y, Tsuge T, Horikoshi S, Emancipator SN and Tomino Y: Down-regulation of core 1 beta 1, 3-galactosylatransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 25:3890–3897. 2010. View Article : Google Scholar : PubMed/NCBI
41	Suzuki H, Suzuki Y, Aizawa M, Yamanaka T, Kihara M, Pang H, Horikoshi S and Tomino Y: Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells. Kidney Int. 72:319–327. 2007. View Article : Google Scholar : PubMed/NCBI
42	Lin FJ, Jiang GR, Shan JP, Zhu C, Zou J and Wu XR: Imbalance of regulatory T cells to Th17 cells in IgA nephropathy. Scand J Clin Lab Invest. 72:221–229. 2010. View Article : Google Scholar
43	Huang H, Peng Y, Liu H, Yang X and Liu F: Decreased CD4+CD25+ cells and increased dimeric IgA-producing cells in tonsils in IgA nephropathy. J Nephrol. 23:202–209. 2010.PubMed/NCBI
44	Chen X, Tang Y, Zhang Y, Zhuo M, Tang Z, Yu Y and Zang G: Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo. Lab Invest. 94:478–490. 2014. View Article : Google Scholar : PubMed/NCBI
45	Quintás-Cardama A and Verstovsek S: Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and resistance. Clin Cancer Res. 19:1933–1940. 2013. View Article : Google Scholar : PubMed/NCBI
46	Shea-Donohue T, Fasano A, Smith A and Zhao A: Enteric pathogens and gut function: Role of cytokines and STATs. Gut Microbes. 1:316–324. 2010. View Article : Google Scholar : PubMed/NCBI